Your Heart Runs on Magnesium And Most of Us Are Running on Empty

When it comes to heart disease, we frequently discuss the oral-systemic connection. The research is known to us. Patients with severe periodontitis are known to have a higher risk of cardiovascular events. We are aware that the oral cavity’s inflammatory load affects vascular tissue downstream.

However, we don’t discuss this enough:

Is that oral inflammation caused by the same nutritional deficiency? Inside the walls of every blood vessel in the body, it is performing a remarkably similar function through entirely parallel mechanisms.

This is the magnesium-cardiovascular story. And it’s one of the most mechanistically compelling cases for a nutritional intervention I’ve ever read in the research.

---

The Discovery of Hard Water and What It Told Us About Magnesium

Let’s begin with a section of epidemiological history that truly intrigues me.

Researchers first noticed a geographic pattern decades ago: communities with hard water, which is naturally mineral-rich and high in calcium and magnesium, had quantifiably lower rates of stroke and cardiovascular death than communities with soft water.

This trend wasn’t subtle. There were enough regional variations in cardiovascular mortality to warrant careful examination. Additionally, the water mineral content continued to show up as a significant factor even after researchers adjusted for other factors like smoking, income, diet, and urbanization.

This pattern was confirmed in the 2024 Cureus review of magnesium’s role in health and disease: areas with hard water, which is high in calcium and magnesium, had lower rates of cardiovascular death. and stroke incidence. Subsequent research confirmed significantly lower cardiovascular death rates in hard-water areas compared to soft-water areas.

This was, in retrospect, one of the first population-level signals that magnesium was doing something important for vascular health something that went far beyond the electrolyte basics we learned in school.

Now we know why.

[Source: Al Alawi et al., Cureus, 2024 DOI: 10.7759/cureus.71392]

---

Magnesium as an Organic Calcium Channel Blocker

This is the mechanism that serves as the foundation for everything else.

Calcium channel blockers are a common class of antihypertensive drugs that you may be familiar with. Diltiazem and amlodipine. Verapamil. They prevent calcium from flooding in and causing vasoconstriction by obstructing voltage-gated calcium channels in vascular smooth muscle cells.

This is a natural function of magnesium.

Magnesium functions as an antagonist of the physiological calcium channel. It prevents too much calcium from entering smooth muscle and heart cells by competing with calcium at the cellular level. Blood vessels relax when magnesium levels are sufficient. Vascular tone returns to normal. Blood pressure either decreases or remains within normal limits.

Calcium is unchecked when magnesium levels are low. Calcium concentrations are higher in smooth muscle cells. Vessels can contract more easily. Vascular resistance rises. The blood pressure increases.

It’s not a metaphor. At the level of the cell membrane, it is the real molecular mechanism.

Oral magnesium improves endothelial dysfunction, raises nitric oxide, acts as a natural calcium channel blocker, and causes both direct and indirect vasodilation, according to a thorough review published in the Journal of Clinical Hypertension. The reviewers discovered that consuming 500–1,000 mg of magnesium daily could lower blood pressure by as much as 5.6/2.8 mmHg. They also discovered that treating hypertension with a combination of increased magnesium and potassium and decreased sodium intake was frequently just as successful as using a single antihypertensive medication.

[Source: Houston M., Journal of Clinical Hypertension, 2011 DOI: 10.1111/j.1751-7176.2011.00538.x]

---

The eNOS Story: Nitric Oxide, Vasodilation, and What Goes Wrong

Nitric oxide (NO) is an extremely important molecule in vascular biology. The endothelium, the single-cell lining of every blood vessel, produces it, and it serves as the body’s primary vasodilator. When the endothelium is healthy and NO production is high, blood vessels remain flexible, elastic, and responsive.

Magnesium directly stimulates endothelial nitric oxide synthase (eNOS), the enzyme responsible for producing NO in endothelial cells.

When magnesium is sufficient:

• eNOS is activated and functional.
• NO is produced at protective levels.
• The vessels dilate appropriately.
• Blood pressure is modulated.
• Vascular inflammation is suppressed

When magnesium is deficient:

• eNOS activity is impaired
• NO production drops
• The body, sensing reduced NO availability, responds by ramping up reactive nitrogen species (RNS) production, a compensatory mechanism that paradoxically increases Vascular inflammation is suppressed.
• In response to metabolic demand, vessels stiffen, become more reactive, and lose the ability to dilate.
• Endothelial dysfunction sets in.

Endothelial dysfunction is not a minor disorder. It is the initial step in atherosclerosis. It occurs before plaque formation. It can be measured many years before a cardiovascular event. According to magnesium research, chronic deficiency is one of the causes.

Critically, this is the same eNOS system involved in the oral-vascular connection discussed in periodontics. The endothelium does not care if the insult is bacterial lipopolysaccharide.(RNS) production a compensatory mechanism that paradoxically increases vascular oxidative stress.doesn’t care whether the insult is bacterial lipopolysaccharide from a periodontal pathogen or the absence of a dietary mineral the impairment looks the same at the cellular level.

---

TRPM7 is the channel that connects magnesium, blood pressure, and vascular inflammation.

This is where cellular biology becomes especially interesting.

TRPM7 (transient receptor potential melastatin 7) is a protein with two functions: an ion channel and a kinase. It is essential for maintaining intracellular magnesium homeostasis. It regulates magnesium transport in and out of vascular smooth muscle cells, cardiac cells, and immune cells.

A 2016 study published in Hypertension looked into what happens when TRPM7 kinase function is compromised. The researchers used mice that were genetically deficient in TRPM7 kinase activity and administered angiotensin II (a hypertension model). The findings were striking:

• TRPM7 kinase deficient mice had lower plasma magnesium at baseline.
• When given angiotensin II, they developed more severe hypertension than normal mice
• Endothelial function was impaired, as measured by decreased acetylcholine-induced vasorelaxation.
• eNOS and Akt (the kinase that phosphorylates and activates eNOS) were downregulated
• Vascular cell adhesion molecule-1 (VCAM-1) was elevated a marker of vascular inflammation that we also see in periodontal patients with cardiovascular comorbidities.
• Cardiac hypertrophy and left ventricular dysfunction were amplified compared to controls

This tells us that TRPM7 kinase is more than just a magnesium transporter. It is a cardiovascular protection system. When magnesium levels are consistently low, and TRPM7 signaling is chronically impaired, the entire architecture of blood pressure regulation and vascular inflammation shifts in a dangerous direction.

[Source: Antunes et al., Hypertension, 2016 DOI: 10.1161/HYPERTENSIONAHA.115.07021]

---

Aldosterone, Thromboxane, and the Vasoconstrictor Cascade

There is another layer to this that receives insufficient attention.

When magnesium is deficient, it actively stimulates the production of molecules that cause vasoconstriction rather than passively allowing it. According to research, magnesium deficiency stimulates:

• Aldosterone synthesis is the hormone that causes sodium and water retention, raising blood pressure.
• Thromboxane production a potent vasoconstrictor and platelet aggregator (which also increases clotting risk).
• Soluble intercellular adhesion molecules promote the binding of inflammatory cells to vessel walls.

Meanwhile, magnesium normally promotes the production of molecules that counteract these effects, including prostacyclin (a vasodilator and platelet inhibitor) and nitric oxide. Deficiency causes the brake to be released while pressing the accelerator.

---

The Arrhythmia Connection

Magnesium’s role in cardiovascular disease extends beyond blood pressure into the electrical system of the heart.

The heart’s rhythm is generated and maintained by a precise choreography of ion movements sodium, potassium, calcium, and magnesium cycling in and out of cardiac muscle cells with extraordinary timing. Magnesium is a cofactor in the Na+/K+/ATPase pump and participates in calcium channel regulation at the level of the cardiac myocyte. When magnesium falls, the electrical stability of the heart falls with it.

Magnesium deficiency is associated with:

• Atrial fibrillation, the most common cardiac arrhythmia, associated with significant stroke risk
• Ventricular tachycardia, a potentially life-threatening rhythm disturbance
• Increased risk of sudden cardiac death through ventricular arrhythmia mechanisms

Intravenous magnesium has been used clinically for decades as an anti-arrhythmic agent. Its use in preeclampsia, eclampsia, and torsades de pointes (a specific and dangerous ventricular rhythm) is well-established. The oral supplementation literature is less definitive for arrhythmia prevention — more research is needed here — but the mechanistic rationale is strong.

What we can say: a patient with chronically low dietary magnesium is operating with reduced myocardial electrical buffering. That’s not a neutral condition.

---

The Magnesium-Cardiovascular Patient in Your Chair

As dental clinicians, we see the cardiovascular patient regularly. They’re on antihypertensives. They may be on diuretics (which, worth noting, dramatically increase urinary magnesium loss and can compound deficiency). They may be on calcium channel blockers, meaning they’re on a drug that does what adequate dietary magnesium does naturally.

The irony is worth naming: some of the most common cardiovascular medications contribute to the magnesium depletion that worsens the condition they’re meant to treat. Thiazide and loop diuretics, in particular, are well-documented causes of urinary magnesium wasting. Beta-blockers, ACE inhibitors, and some statins have also been associated with altered magnesium metabolism.

I’m not suggesting you’re managing their cardiovascular medications. You’re not. But you are seeing these patients every six months, taking their blood pressure readings, noticing their inflammatory burden, updating their health histories. You have a window.

And when a patient tells you they’re on a diuretic, or a proton pump inhibitor, or they’ve been feeling exhausted and crampy and anxious, the magnesium question is a reasonable and evidence-informed one to put in their chart and in their ear.

---

What the Supplementation Research Shows

The evidence for magnesium supplementation in cardiovascular health is meaningful, though not without nuance.

Meta-analyses and systematic reviews support an inverse relationship between dietary magnesium intake and hypertension prevalence. Oral supplementation has shown improvements in endothelial function, reductions in blood pressure in both hypertensive and normotensive individuals, and reductions in inflammatory markers.

The Journal of Clinical Hypertension review found that combining increased magnesium with increased potassium and decreased sodium intake was often equivalent to the effect of a single antihypertensive medication. This doesn’t mean supplements replace medication. It means the dietary mineral environment matters more than most cardiovascular care conversations acknowledge.

Practical guidance based on the research:

• Cardiovascular support: 300–600 mg/day, typically studied over 3–12 months
• Blood pressure reduction: meaningful effects seen within 3–6 months of consistent intake
• Form matters: Magnesium glycinate and citrate for better bioavailability; oxide forms poorly absorbed
• Food sources: mineral-rich water, pumpkin seeds, dark leafy greens, almonds, dark chocolate, legumes

One additional note: Magnesium potentiates all classes of antihypertensive medications. According to the same review, adequate magnesium levels actually increase the effectiveness of antihypertensive drugs. So in a patient already on cardiovascular medication, addressing magnesium status isn’t competing with their treatment it may be reinforcing it.

Test your Magnesium here. Use AmberA10 at checkout.

---

Coming Up Next

We’ve now established magnesium’s role in two of the most common chronic conditions our patients are managing: periodontal disease and cardiovascular disease.

In Article 3, we’re going into the metabolic dimension the magnesium-insulin resistance connection, what it means for HbA1c and HOMA-IR, and why the diabetes patient in your chair is almost certainly running low on the very mineral their body needs to manage glucose.

---

Content is educational and not intended as individualized medical advice.

Disclosure: I partner with Equilife because I use and trust their formulations. If you purchase through my link, I may earn a commission at no additional cost to you.

---

The Science

Based on research retrieved from PubMed:

1. Al Alawi AM et al. “Magnesium Matters: A Comprehensive Review.” Cureus. 2024. DOI: 10.7759/cureus.71392
2. Houston M. “The role of magnesium in hypertension and cardiovascular disease.” Journal of Clinical Hypertension. 2011. DOI: 10.1111/j.1751-7176.2011.00538.x
3. Antunes TT et al. “Transient Receptor Potential Melastatin 7 Cation Channel Kinase: New Player in Angiotensin II-Induced Hypertension.” Hypertension. 2016. DOI: 10.1161/HYPERTENSIONAHA.115.07021

---

Amber Auger, MPH, RDH Functional Hygienist, clinician, and advocate for whole-person care. Because the health conversation doesn’t stop at the gumline.